Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain Tumor's hidden electrical signals could reveal its weaknesses

NCT ID NCT07616726

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a special brain scan called magnetoencephalography (MEG) can detect electrical differences within gliomas, the most common malignant brain tumors in adults. Researchers will scan 60 newly diagnosed patients before surgery to see if MEG can identify more aggressive tumor areas. The goal is to better understand why these tumors resist treatment and find new ways to attack them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to new ways to understand why some parts of a glioma are more aggressive and resistant to treatment, potentially guiding future therapies.
What could go wrong
This is an early feasibility study with only 60 participants, so it may not produce clear or generalizable results. MEG recordings may not reliably capture tumor heterogeneity in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged over 18 * With a newly diagnosed malignant glioma based on brain imaging * Eligible for surgical removal * Having given their consent Exclusion Criteria: * Contraindications to Magnetic resonance imaging (MRI) (claustrophobia, metallic implants, particularly intraocular implants, pacemakers) * Contraindications to magnetoencephalography (MEG) (metallic implants in the mouth-dentures, fillings, crowns) * Coagulation disorders * Pregnancy, breastfeeding, or patients not using effective contraception * Subjects participating in another interventional study with an exclusion period still in progress at the time of pre-inclusion, etc. * Subjects deprived of their liberty by judicial or administrative decision * Subjects receiving psychiatric care * Subjects admitted to a health or social care facility for purposes other than research * Adult subjects subject to legal protection measures (guardianship, curatorship) * Subjects not affiliated with a social security system or beneficiaries of a similar system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant glioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patients diagnosed with A malignant glioma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Bron, 69800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.